Orchid Pharma (ORCHPHARMA)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me look at Orchid Pharma the way Graham would: price is what you pay, value is what you get. At ₹566.80, the market values it at ₹3,143 Cr—that is 120.99 times trailing earnings, yet the latest quarter produced a net loss of ₹13 Cr on sales of ₹207 Cr. That is not a sign of business quality. Return on equity is just 3.34%, return on capital employed is only 8.07%, sales are shrinking 4.63%, and profit growth has collapsed 126.47%. These are not the numbers of a company with a durable moat. The Piotroski F-score of 3/9 reinforces my concern about financial health. Book value is ₹261.46, but I am asked to pay 2.17 times book; the asset cushion is not enough, and I am paying a large premium to net assets. There is no dividend yield, so I receive nothing while I wait. Graham would demand either cheapness or growth; I see neither. Promoter holding of 69.84% is a positive for alignment, but even that cannot turn a weak business into an attractive investment. The 52-week range of ₹480 to ₹1,133 shows how much this stock has swung; being near the lower end does not automatically create a margin of safety. This may eventually be a turnaround, but I do not buy possibilities; I buy demonstrated earning power. I would need to see rising sales, positive profits, and higher returns on capital. Today, the FairStock Score of 0/100 and my own discipline both say: avoid.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer